Biosensor measurement of purine release from cerebellar cultures and slices

Purinergic Signalling

Volumn 6, Issue 3, 2010, Pages 339-348

  Wall, Mark ^a   Eason, Robert ^a   Dale, Nicholas ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Biosensor; ENT; Glia; Granule cell; Inosine

Indexed keywords

EID: 77957292166     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-010-9185-8     Document Type: Article

References (34)

1. Boison D (2006) Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmcol Sci 27: 652-658.
2. Jacobson KA, Gao Z (2006) Adenosine receptors as therapeutic targets. Nature Reviews 5: 247-264.
3. Dale N, Frenguelli B (2007) Release of adenosine and ATP during ischemia and epilepsy. Curr Neuropharmacol 7: 160-179.
4. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-252.
5. Fredholm BB (2003) Adenosine receptors as targets for drug development. Drug News Perspect 16: 283-289.
6. Wall MJ, Dale N (2008) Activity-dependent release of adenosine: a critical re-evaluation of mechanism. Curr Neuropharmacol 6: 329-337.
7. Latini S, Pedata F (2001) Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79: 463-484.
8. Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87: 659-797.
9. Jo YH, Schlichter R (1999) Synaptic co-release of ATP and GABA in cultured spinal neurons. Nat Neurosci 2: 241-245.
10. Pearson RA, Dale N, Llaudet E, Mobbs P (2005) ATP released via gap junction hemichannels from the pigment epithelium regulates neural retinal progenitor proliferation. Neuron 46: 731-44.
11. Sweeney MI (1996) Adenosine release and uptake in cerebellar granule neurons both occur via an equilibrative nucleoside carrier that is modulated by G proteins. J Neurochem 67: 81-88.
12. Craig CG, White TD (1993) N-methyl-d-aspartate and non-N-methyl-d-aspartate-evoked adenosine release from rat cortical slices: distinct purinergic sources and mechanisms of release. J Neurochem 60: 1073-1080.
13. Wall MJ, Dale N (2007) Auto-inhibition of parallel fibre-Purkinje cell synapses by activity dependent adenosine release. J Physiol 581: 553-566.
14. Llaudet E, Botting N, Crayston J, Dale N (2003) A three enzyme microelectrode sensor for detecting purine release from central nervous system. Biosens Bioelectron 18: 43-52.
15. Llaudet E, Hatz S, Droniou M, Dale N (2005) Microelectrode biosensor for real-time measurement of ATP in biological tissue. Anal Chem 77: 3267-3273.
16. Tomasellia B, Zur Nedden S, Podhraski V, Baier-Bitterlich B (2008) MAPK is an essential effector for purine nucleoside-mediated neuroprotection of hypoxic PC12 cells and primary cerebellar granule neurons. Mol Cell Neurosci 38: 559-568.
17. Frenguelli BG, Llaudet E, Dale N (2003) High-resolution real-time recording with microelectrode biosensors reveals novel aspects of adenosine release during hypoxia in rat hippocampal slices. J Neurochem 86: 1506-15.
18. Parkinson FE, Xiong W (2004) Stimulus- and cell-type-specific release of purines in cultured rat forebrain astrocytes and neurons. J Neurochem 88: 1305-1312.
19. Noji T, Karaswa A, Kusaka H (2004) Adenosine uptake inhibitors. Eur J Pharm 495: 1-16.
20. Wall MJ, Atterbury A, Dale N (2007) Control of basal extracellular adenosine concentration in rat cerebellum. J Physiol 582: 137-152.
21. Atterbury A, Wall MJ (2009) Adenosine signalling at immature parallel fibre-Purkinje cell synapses in rat cerebellum. J Physiol 587: 4497-4509.
22. Parkinson FE, Sinclair CJ, Othman T, Haughey NJ, Geiger JD (2002) Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions. Neuropharmacology 43: 836-46.
23. Schultz V, Lowenstein JM (1976) Purine nucleotide cycle: evidence for the occurrence of the cycle in brain. J Biol Chem 251: 485-492.
24. Norenberg MD, Rao KV, Jayakumar AR (2005) Mechanisms of ammonia-induced astrocyte swelling. Metab Brain Dis 20: 303-318.
25. Sinclair CJ, LaRivière CG, Young JD, Cass CE, Baldwin SA, Parkinson FE (2000) Purine uptake and release in rat C6 glioma cells: nucleoside transport and purine metabolism under ATP-depleting conditions. J Neurochem 75: 1528-38.
26. Almaraz L, García-Sancho J (1989) Activation by calcium of AMP deaminase from the human red cell. FEBS Lett 244: 417-20.
27. Mahnke DK, Sabina RL (2005) Calcium activates erythrocyte AMP deaminase [isoform E (AMPD3)] through a protein-protein interaction between calmodulin and the N-terminal domain of the AMPD3 polypeptide. Biochemistry 44: 5551-9.
28. Guinzberg R, Cortés D, Díaz-Cruz A, Riveros-Rosas H, Villalobos-Molina R, Piña E (2006) Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors. Am J Physiol Endocrinol Metab 290: 940-51.
29. Hasko G, Sitkovsky MV, Szabo C (2004) Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 25: 152-157.
30. Zurn AD, Do KQ (1988) Purine metabolite inosine is an adrenergic neurotrophic substance for cultured chicken sympathetic neurons. Proc Natl Acad Sci U S A 85: 8301-5.
31. Braumann T, Jastorff B, Richter-Landsberg C (1986) Fate of cyclic nucleotides in PC12 cell cultures: uptake, metabolism, and effects of metabolites on nerve growth factor-induced neurite outgrowth. J Neurochem 47: 912-9.
32. Rathbone MP, Middlemiss PJ, Crocker CE, Glasky MS, Juurlink BH, Ramirez JJ, Ciccarelli R, Di Iorio P, Caciagli F (1999) AIT-082 as a potential neuroprotective and regenerative agent in stroke and central nervous system injury. Expert Opin Investig Drugs 8: 1255-62.
33. Mink R, Johnston J (2007) The effect of infusing hypoxanthine or xanthine on hypoxic-ischemic brain injury in rabbits. Brain Res 1147: 256-64.
34. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66: 1460-8.